A
Aimee M. Crago
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 76
Citations - 4275
Aimee M. Crago is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 25, co-authored 60 publications receiving 3192 citations. Previous affiliations of Aimee M. Crago include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors
Juliann Chmielecki,Aimee M. Crago,Mara Rosenberg,Rachael O'Connor,Sarah R. Walker,Sarah R. Walker,Lauren Ambrogio,Daniel Auclair,Aaron McKenna,Michael Heinrich,David A. Frank,David A. Frank,Matthew Meyerson,Matthew Meyerson +13 more
TL;DR: Analysis in 53 tumors confirmed the presence of 7 variants of this fusion transcript in 29 tumors, representing a lower bound for fusion frequency at this locus and suggesting that the NAB2-STAT6 fusion is a distinct molecular feature of SFTs.
Journal Article
Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells
Robin E. Bachelder,Aimee M. Crago,Jun Chung,Melissa A. Wendt,Leslie M. Shaw,Gregory Robinson,Arthur M. Mercurio +6 more
TL;DR: A novel function for the vascular endothelial growth factor (VEGF) in its ability to stimulate an autocrine signaling pathway in metastatic breast carcinoma cells that is essential for their survival is identified.
Journal ArticleDOI
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Mark A. Dickson,William D. Tap,Mary Louise Keohan,Sandra P. D'Angelo,Mrinal M. Gounder,Cristina R. Antonescu,Jonathan Landa,Li-Xuan Qin,Dustin D. Rathbone,Mercedes M. Condy,Yelena Ustoyev,Aimee M. Crago,Samuel Singer,Gary K. Schwartz +13 more
TL;DR: Treatment with theCDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
Journal ArticleDOI
Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma.
Marcus C.B. Tan,Murray F. Brennan,Deborah Kuk,Narasimhan P. Agaram,Cristina R. Antonescu,Li-Xuan Qin,Nicole Moraco,Aimee M. Crago,Samuel Singer +8 more
TL;DR: Histologic type/subtype is the most important independent predictor of DSD, LR, and DR in primary retroperitoneal sarcoma and will aid in more accurate patient counseling and selection of patients for adjuvant therapy trials.
Journal ArticleDOI
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial
Mark A. Dickson,Gary K. Schwartz,Mary Louise Keohan,Mary Louise Keohan,Sandra P. D'Angelo,Sandra P. D'Angelo,Mrinal M. Gounder,Mrinal M. Gounder,Ping Chi,Ping Chi,Cristina R. Antonescu,Jonathan Landa,Li-Xuan Qin,Aimee M. Crago,Samuel Singer,Samuel Singer,Andrew Koff,William D. Tap,William D. Tap +18 more
TL;DR: In patients with advanced WD/DDLS, treatment with palbociclib was associated with a favorable PFS and occasional tumor response and this dose and schedule appears active and may have less toxic effects than 200 mg for 14 days.